Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success
BeyondSpring has been on a roll lately.
Just a few weeks ago, the New York-based biotech shocked investors and analysts with how effective the company’s molecule, plinabulin, was on cancer patients’ longevity. Now, the biotech has forged a deal with a major player in the Asian market for the drug.
BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.